Sunday, July 12, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “inhibitors”

2,466 pharma patents match "inhibitors" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,466
Index total 30,257
Page 38 / 103

Quick answer

This filtered view shows 2,466 pharmaceutical patents matching "inhibitors" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,466 results for “inhibitors” · 30,257 patents in full index Clear search

  1. US 10335404

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted

  2. US 10336773

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted

  3. US 10337005

    Oligonucleotide-based inhibitors comprising locked nucleic acid motif

    MIRAGEN THERAPEUTICS, INC. · Granted Jul 2, 2019 · Expires Jun 27, 2039

    granted

  4. US 10329298

    Inhibitors of cellular metabolic processes

    Agios Pharmaceuticals, Inc. · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted

  5. US 10329283

    G protein-coupled receptor kinase inhibitors and methods for use of the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted

  6. US 10329260

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted

  7. US 10316371

    Screening methods for identifying specific Staphylococcus aureus inhibitors

    TRANA DISCOVERY, INC. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  8. US 10314908

    Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

    The United States of America as represented by the Secretary of the Department of · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  9. US 10316038

    Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer

    Aclaris Therapeutics, Inc. · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  10. US 10315984

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jun 11, 2019 · Expires Jun 6, 2039

    granted

  11. US 10308605

    Proton pump inhibitors

    Takeda Pharmaceutical Company Limited · Granted Jun 4, 2019 · Expires May 30, 2039

    granted

  12. US 10307423

    FBXO3 inhibitors

    United States Government as represented by the Department of Veterans Affairs · Granted Jun 4, 2019 · Expires May 30, 2039

    granted

  13. US 10307407

    9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jun 4, 2019 · Expires May 30, 2039

    granted

  14. US 10308608

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Jun 4, 2019 · Expires May 30, 2039

    granted

  15. US 10308656

    Small molecule inhibitors of Ku70/80 and uses thereof

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Jun 4, 2019 · Expires May 30, 2039

    granted

  16. US 10300107

    Compositions and methods for CaMKII inhibitors and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted May 28, 2019 · Expires May 23, 2039

    granted

  17. US 10301323

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted May 28, 2019 · Expires May 23, 2039

    granted

  18. US 10301317

    Inhibitors of ERK and methods of use

    Kura Oncology, Inc. · Granted May 28, 2019 · Expires May 23, 2039

    granted

  19. US 10300073

    Use of CDK9 and BRD4 inhibitors to inhibit inflammation

    The Regents of the University of California · Granted May 28, 2019 · Expires May 23, 2039

    granted

  20. US 10293022

    Peptide inhibitors of serotonin 5-HT2C receptor:PTEN interaction

    THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYTEM · Granted May 21, 2019 · Expires May 16, 2039

    granted

  21. US 10292979

    Methods of treating cancer patients with farnesyltransferase inhibitors

    Kura Oncology, Inc. · Granted May 21, 2019 · Expires May 16, 2039

    granted

  22. US 2019144465

    Macrocyclic MCL-1 inhibitors and methods of use

    ABBVIE INC [US] · Granted May 16, 2019 · Expires May 11, 2039

    granted

  23. US 10287279

    Inhibitors of human 12/15-lipoxygenase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 14, 2019 · Expires May 9, 2039

    granted

  24. US 10287295

    TGF-β inhibitors

    Rigel Pharmaceuticals, Inc. · Granted May 14, 2019 · Expires May 9, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.